Issue Date: May 8, 2017
Daiichi invests in antibody-drug combos
Daiichi Sankyo will spend about $135 million to enhance its manufacturing capabilities in Japan for antibody-drug conjugates. ADCs link a cytotoxic molecule to an antibody that binds selectively to a target on cancer cells. The company says the investment, in three of its Japanese plants, will improve its ability to make ADCs for investigational and clinical use. Daiichi is developing six ADCs, including two in Phase I clinical trials.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society